This selection from the NCCN Guidelines for Rectal Cancer focuses on management of
malignant polyps and resectable nonmetastatic rectal cancer because important updates …

There is a large variability regarding the definition and choice of primary endpoints in phase
2 and phase 3 multimodal rectal cancer trials, resulting in inconsistency and difficulty of data …

Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide
and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) …

PURPOSE To ascertain if preoperative short-term radiotherapy followed by chemotherapy is
not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally …

Background Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery,
and adjuvant chemotherapy controls local disease, but distant metastases remain common …

Oxaliplatin resistance is a challenge in the treatment of colorectal cancer (CRC) patients.
Regulatory T cells (Tregs) are well known for their immunosuppressive roles, and targeting …

As a DNA damaging agent, oxaliplatin (OXA) can induce immunogenic cell death (ICD) in
tumors to activate the immune system. However, the DNA damage induced by OXA is limited …

Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients
are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients. There is …

Background/Aim: Rectal cancer is a recalcitrant disease with limited treatment options. Pre-
clinical studies have shown the efficacy of methionine restriction with a low-methionine diet …

The introduction of checkpoint inhibitors provided remarkable achievements in several solid
tumors but only 5% of metastatic colorectal cancer (mCRC) patients, ie, those with bearing …